Anlotinib Plus Osimertinib in Osimertinib‐Resistant Nonsquamous Nonsmall Cell Lung Cancer With Gradual Progression: A Retrospective Study

ABSTRACT Background Previous studies have shown that anlotinib plus third‐generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) overcome acquired resistance to EGFR‐TKIs in patients with advanced EGFR‐mutant nonsmall cell lung cancer (NSCLC). This study aimed to retrospe...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Yu Hua, Minghui Liu, Boshi Li, Hongbing Zhang, Zihe Zhang, Yanan Wang, Jinghao Liu, Xin Li, Yongwen Li, Sen Wei, Hongyu Liu, Jun Chen
Natura: Artigo
Lingua:Inglês
Pubblicazione: Wiley 2025-05-01
Serie:Thoracic Cancer
Soggetti:
anlotinib
nonsquamous nonsmall cell lung cancer
osimertinib
resistance
Accesso online:https://doi.org/10.1111/1759-7714.70071
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi